Isolagen, Inc. Completes Enrollment in Isolagen Therapy(TM) Phase II/III Acne ...(ons concerning future events and are sub...),Health

Date:3/14/2008

ons concerning future events and are subject to a number of risks, uncertainties, and other factors, many of which are outside of our control, that could cause actual results to materially differ from such statements. Such risks, uncertainties, and other factors include, but are not necessarily limited to, those set forth under Item 1A "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2007, as updated in "Item 1A. Risk Factors" in the Company's Quarterly Reports on Form 10-Q filed since the annual report. We operate in a highly competitive and rapidly changing environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. We disclaim any intention to, and undertake no obligation to, update or revise any forward-looking statements. Readers are also urged to carefully review and consider the other various disclosures in the Company's Annual Report on Form 10-K for the year ended December 31, 2007, as well as other public filings with the SEC since such date.

'/>"/>

SOURCE Isolagen, Inc. Copyright©2008 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3
Related medicine technology :

1. NanoBio(R) Corporation Completes $30 Million in Equity Funding by Meeting Key Development Milestones
2. Pharmacopeia Completes Enrollment in Phase 2 Hypertension Study with PS433540 (DARA)
3. MonoSol Rx Completes Thin Film Ondansetron Pilot Bioequivalence Study
4. Horizon Therapeutics Completes Enrollment in Phase 3 Trials for Lead Product Candidate HZT-501
5. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
6. Isolagen Inc. Completes Injections of Isolagen Therapy(TM) in Phase III Wrinkle and Phase II Full Face Studies
7. Nastech Completes Enrollment of Phase 2 Clinical Trial of PYY3-36 Nasal Spray to Treat Obesity
8. Biodel Inc. Completes Enrollment of Two Pivotal Phase III Clinical Trials of VIAject(TM) and Plans Manufacturing Facility for VIAject(TM)
9. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
10. NicOx Completes Enrollment in Second Pivotal Phase 3 Study for Naproxcinod and Provides Development Update
11. YMed, Inc. Successfully Completes First Clinical Cases With Innovative VascuTraK(TM) II PTA Dilatation Catheter